access intranet after hours circle-arrow apply blog caret circle arrow close closer look community outreach community outreach contact contact us down arrow facebook lock solid find a provider find a clinical trial find a provider find a researcher find faculty find-a-service how to apply join leadership left arrow locations logo make a gift map location maximize minimize my chart my chart notification hp notification lp next chevron right nxt prev pay your bill play previous quality and safety refer a patient request a speaker request appointment request an appointment residents corner rss search search jobs Asset 65 submit a story idea symptom checker Arrow Circle Up twitter youtube Dino Logo External Link University Logo Color University Logo Solid Health Logo Solid Arrow Right Circle Book Calendar Date Calendar Search Date Diploma Certificate Dollar Circle Donate Envelope Graduation Cap Map Pin Map Search Phone Pills Podcast
Zile Lab Image

Zile Research Lab

Michael R. Zile, M.D.Michael Zile, M.D.

Professor and Charles Ezra Daniel Endowed Chair
Division of Cardiology

Effective management of patients with chronic heart failure (CHF) remains one of the most critical unmet needs in cardiology in the United States and in the world. The fundamental goals of our research efforts over the last 35 years have been to define the ventricular, myocardial, cellular, and molecular mechanisms that cause the development and the progression of CHF and then to use these identified mechanisms as targets to improve diagnostic techniques, prognostic prediction, and therapeutic management of patients with CHF. In particular, I have focused my efforts on the clinical syndrome of heart failure (HF) with a preserved ejection fraction (HFpEF). More than 50% of all HF patients have HFpEF. HFpEF results in morbidity and mortality rates that are staggering: 50 to 60% 5-year mortality rate, 50% 6-month rehospitalization rate, and severe clinical disability. However, as stated in the current HF guidelines: “to date, no treatment management strategies have yet been shown, convincingly, to reduce morbidity or mortality in patients with HFpEF”.

Together with collaborators, we have developed state-of-the-art imaging techniques to characterize the structural and functional remodeling that occur in CHF patients. In addition, we have applied these techniques in an echocardiographic core laboratory used for all of our clinical, translational, and basic science studies. We have also developed clinically relevant animal models of human disease, state-of-the-art methods to assess cardiovascular remodeling, extracellular matrix homeostasis and myocardial function, and applied innovative advanced progenitor cell, transgenic and viral-based alterations in gene expression, translation, and activity to define the pathophysiologic mechanisms underlying CHF.

The Zile laboratory has been supported by research grants from the National Heart, Lung and Blood Institute, the American Heart Association, the Medical University of South Carolina, the National Aeronautics and Space Administration, the United States Department of Veterans Affairs, the United States Department of Defense.


PubMed Collection